Hospira Announces Voluntary Nationwide Recall Of One Lot Of Lidocaine HCI Injection, USP, 2 percent, 20 mg per mL Single-dose Vial, Preservative-free, Due To Particulate Matter

You are subscribed to Recalls, Market Withdrawals and Safety Alerts for U.S. Food & Drug Administration (FDA).

This information has recently been updated and is now available.

 

Hospira Announces Voluntary Nationwide Recall Of One Lot Of Lidocaine HCI Injection, USP, 2 percent, 20 mg per mL Single-dose Vial, Preservative-free, Due To Particulate Matter

07/29/2014 03:39 PM EDT

Hospira, Inc. (NYSE: HSP), announced today it will initiate a voluntary recall of one lot of Lidocaine HCI Injection, USP, 2 percent, 20 mg per mL, 5 mL single-Dose Vial, Preservative-Free (NDC 0409-2066-05; Lot 25-550-DD, Expiry 1JAN2015) to the user level due to a confirmed customer report of discolored product with visible particles in the solution as well as particulate embedded in the molded glass container. Hospira has identified the particulate as iron oxide. To date, Hospira has not received reports of any adverse events associated with this issue for this lot.

. For detailed information pertaining to this Recalls, Market Withdrawals and Safety Alerts message, please click the link at the beginning of this bulletin.

---

Manage your FDA Subscriptions:

• Update your preferences or unsubscribe
• Questions about this service? Please visit subscriberhelp.govdelivery.com
• Other inquiries? webmail@oc.fda.gov

---

This email was sent to filter@clubhouseb.com using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420